Concepts (245)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Surgical Mesh | 19 | 2018 | 47 | 6.190 |
Why?
|
| Urinary Incontinence, Stress | 20 | 2019 | 65 | 5.890 |
Why?
|
| Pelvic Organ Prolapse | 14 | 2020 | 46 | 4.420 |
Why?
|
| Prostatic Hyperplasia | 17 | 2020 | 56 | 2.970 |
Why?
|
| Urinary Bladder, Overactive | 7 | 2020 | 16 | 2.680 |
Why?
|
| Uterine Prolapse | 7 | 2018 | 21 | 2.180 |
Why?
|
| Urinary Incontinence | 6 | 2018 | 48 | 2.180 |
Why?
|
| Suburethral Slings | 6 | 2020 | 14 | 2.140 |
Why?
|
| Urethra | 6 | 2019 | 103 | 1.770 |
Why?
|
| Ablation Techniques | 9 | 2020 | 26 | 1.510 |
Why?
|
| Urodynamics | 8 | 2020 | 37 | 1.490 |
Why?
|
| Biocompatible Materials | 6 | 2014 | 218 | 1.450 |
Why?
|
| Pelvic Floor | 7 | 2017 | 20 | 1.390 |
Why?
|
| Urology | 3 | 2014 | 37 | 1.380 |
Why?
|
| Prostate | 8 | 2020 | 74 | 1.220 |
Why?
|
| Prostatectomy | 7 | 2020 | 90 | 1.210 |
Why?
|
| Humans | 74 | 2020 | 32297 | 1.210 |
Why?
|
| Urologic Diseases | 4 | 2014 | 28 | 1.170 |
Why?
|
| Vagina | 6 | 2020 | 58 | 1.150 |
Why?
|
| Urologic Surgical Procedures | 6 | 2018 | 64 | 1.030 |
Why?
|
| Regenerative Medicine | 3 | 2019 | 196 | 0.980 |
Why?
|
| Prostheses and Implants | 4 | 2018 | 42 | 0.970 |
Why?
|
| Prosthesis Failure | 2 | 2015 | 44 | 0.940 |
Why?
|
| Cystitis, Interstitial | 6 | 2020 | 45 | 0.910 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2020 | 353 | 0.910 |
Why?
|
| Female | 42 | 2020 | 20126 | 0.910 |
Why?
|
| Urinary Catheterization | 3 | 2020 | 18 | 0.870 |
Why?
|
| Transurethral Resection of Prostate | 6 | 2020 | 8 | 0.860 |
Why?
|
| Algorithms | 4 | 2018 | 497 | 0.840 |
Why?
|
| Stents | 4 | 2015 | 180 | 0.820 |
Why?
|
| Polypropylenes | 3 | 2012 | 6 | 0.760 |
Why?
|
| Postoperative Complications | 9 | 2020 | 788 | 0.740 |
Why?
|
| Internship and Residency | 3 | 2014 | 306 | 0.720 |
Why?
|
| Urinary Bladder Diseases | 3 | 2020 | 22 | 0.720 |
Why?
|
| Urinary Bladder | 7 | 2019 | 185 | 0.710 |
Why?
|
| Tissue Engineering | 2 | 2019 | 647 | 0.710 |
Why?
|
| Gynecologic Surgical Procedures | 3 | 2020 | 46 | 0.700 |
Why?
|
| Urinary Bladder Neck Obstruction | 2 | 2017 | 6 | 0.680 |
Why?
|
| Reconstructive Surgical Procedures | 4 | 2020 | 199 | 0.670 |
Why?
|
| Hydronephrosis | 1 | 2017 | 15 | 0.620 |
Why?
|
| Ureteral Diseases | 1 | 2017 | 8 | 0.620 |
Why?
|
| Treatment Outcome | 17 | 2020 | 3358 | 0.590 |
Why?
|
| Prosthesis Design | 2 | 2015 | 92 | 0.580 |
Why?
|
| Water | 8 | 2020 | 57 | 0.580 |
Why?
|
| Urethral Obstruction | 1 | 2015 | 4 | 0.530 |
Why?
|
| Aged | 28 | 2020 | 10398 | 0.530 |
Why?
|
| Exercise Therapy | 2 | 2018 | 259 | 0.520 |
Why?
|
| Medical Device Recalls | 1 | 2015 | 2 | 0.510 |
Why?
|
| Public Opinion | 1 | 2014 | 19 | 0.490 |
Why?
|
| Device Removal | 2 | 2012 | 33 | 0.480 |
Why?
|
| Male | 29 | 2020 | 19488 | 0.470 |
Why?
|
| Compensation and Redress | 1 | 2013 | 3 | 0.470 |
Why?
|
| Malpractice | 1 | 2013 | 22 | 0.460 |
Why?
|
| Liability, Legal | 1 | 2013 | 25 | 0.460 |
Why?
|
| Muscle Contraction | 2 | 2018 | 114 | 0.460 |
Why?
|
| Quality of Life | 6 | 2019 | 915 | 0.450 |
Why?
|
| Myoblasts | 3 | 2017 | 38 | 0.420 |
Why?
|
| Tissue Transplantation | 1 | 2012 | 16 | 0.410 |
Why?
|
| Prosthesis Implantation | 2 | 2015 | 40 | 0.390 |
Why?
|
| Collagen | 4 | 2017 | 228 | 0.380 |
Why?
|
| Middle Aged | 24 | 2020 | 11949 | 0.360 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2014 | 511 | 0.350 |
Why?
|
| Retrospective Studies | 12 | 2020 | 3514 | 0.340 |
Why?
|
| Muscarinic Antagonists | 1 | 2009 | 15 | 0.340 |
Why?
|
| Animals | 12 | 2019 | 7694 | 0.330 |
Why?
|
| Dietary Proteins | 1 | 2008 | 51 | 0.320 |
Why?
|
| Physical Therapy Modalities | 2 | 2019 | 65 | 0.320 |
Why?
|
| Soybean Proteins | 1 | 2008 | 64 | 0.310 |
Why?
|
| Postoperative Hemorrhage | 2 | 2018 | 41 | 0.300 |
Why?
|
| Urethral Diseases | 2 | 2018 | 18 | 0.290 |
Why?
|
| Aged, 80 and over | 9 | 2019 | 4050 | 0.290 |
Why?
|
| Stroke | 1 | 2012 | 585 | 0.290 |
Why?
|
| Microwaves | 2 | 2008 | 8 | 0.270 |
Why?
|
| Pelvic Pain | 2 | 2017 | 18 | 0.260 |
Why?
|
| Recovery of Function | 2 | 2020 | 201 | 0.260 |
Why?
|
| Forecasting | 2 | 2018 | 145 | 0.250 |
Why?
|
| Diathermy | 1 | 2004 | 1 | 0.250 |
Why?
|
| Prevalence | 3 | 2017 | 986 | 0.240 |
Why?
|
| Follow-Up Studies | 5 | 2015 | 2296 | 0.240 |
Why?
|
| Organ Size | 6 | 2020 | 220 | 0.240 |
Why?
|
| Time Factors | 8 | 2020 | 2181 | 0.240 |
Why?
|
| Prostatic Neoplasms | 3 | 2018 | 492 | 0.220 |
Why?
|
| Peptides | 1 | 2004 | 120 | 0.220 |
Why?
|
| Adult | 9 | 2020 | 9467 | 0.210 |
Why?
|
| Syndrome | 2 | 2020 | 74 | 0.210 |
Why?
|
| Urethral Stricture | 2 | 2017 | 31 | 0.210 |
Why?
|
| Prospective Studies | 8 | 2020 | 2274 | 0.200 |
Why?
|
| Risk Assessment | 2 | 2017 | 1447 | 0.190 |
Why?
|
| Erectile Dysfunction | 2 | 2018 | 56 | 0.190 |
Why?
|
| Endoscopy | 2 | 2019 | 57 | 0.180 |
Why?
|
| Urinary Retention | 1 | 2020 | 8 | 0.180 |
Why?
|
| Chemokine CXCL12 | 2 | 2018 | 25 | 0.180 |
Why?
|
| Incidence | 2 | 2014 | 1207 | 0.180 |
Why?
|
| Hospitals | 1 | 2020 | 99 | 0.170 |
Why?
|
| Macaca fascicularis | 4 | 2018 | 401 | 0.170 |
Why?
|
| Polyneuropathies | 1 | 2019 | 10 | 0.170 |
Why?
|
| Hydrotherapy | 1 | 2019 | 4 | 0.170 |
Why?
|
| Endometriosis | 1 | 2020 | 98 | 0.170 |
Why?
|
| Fibromyalgia | 1 | 2019 | 25 | 0.170 |
Why?
|
| Anesthesia | 1 | 2019 | 64 | 0.160 |
Why?
|
| Hernia, Inguinal | 1 | 2018 | 2 | 0.160 |
Why?
|
| Pubic Symphysis Diastasis | 1 | 2018 | 3 | 0.160 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2010 | 69 | 0.160 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2018 | 9 | 0.160 |
Why?
|
| Preoperative Period | 1 | 2018 | 35 | 0.160 |
Why?
|
| Electric Stimulation Therapy | 1 | 2018 | 16 | 0.160 |
Why?
|
| Patient Positioning | 1 | 2018 | 23 | 0.160 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2018 | 17 | 0.160 |
Why?
|
| Electrocoagulation | 1 | 2018 | 12 | 0.160 |
Why?
|
| Postoperative Period | 1 | 2018 | 100 | 0.150 |
Why?
|
| Adenoma | 1 | 2018 | 39 | 0.150 |
Why?
|
| Aging | 3 | 2017 | 953 | 0.150 |
Why?
|
| Risk Factors | 5 | 2020 | 3876 | 0.150 |
Why?
|
| Cost of Illness | 1 | 2017 | 70 | 0.150 |
Why?
|
| Double-Blind Method | 4 | 2020 | 550 | 0.150 |
Why?
|
| Elastin | 2 | 2014 | 14 | 0.150 |
Why?
|
| Spinal Cord Injuries | 1 | 2017 | 38 | 0.150 |
Why?
|
| Nervous System Diseases | 1 | 2017 | 42 | 0.150 |
Why?
|
| Behavior Therapy | 1 | 2018 | 102 | 0.150 |
Why?
|
| RNA | 2 | 2016 | 95 | 0.150 |
Why?
|
| Patient Satisfaction | 2 | 2010 | 245 | 0.140 |
Why?
|
| Self Care | 1 | 2018 | 145 | 0.140 |
Why?
|
| Control Groups | 1 | 2016 | 5 | 0.140 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 217 | 0.140 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 90 | 0.140 |
Why?
|
| Databases, Factual | 2 | 2017 | 355 | 0.140 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 525 | 0.130 |
Why?
|
| Education, Medical, Graduate | 2 | 2014 | 126 | 0.130 |
Why?
|
| Laser Therapy | 1 | 2015 | 55 | 0.130 |
Why?
|
| Frail Elderly | 1 | 2015 | 70 | 0.130 |
Why?
|
| Gene Expression | 1 | 2016 | 345 | 0.130 |
Why?
|
| United States | 2 | 2014 | 3983 | 0.120 |
Why?
|
| Severity of Illness Index | 4 | 2019 | 926 | 0.120 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 1040 | 0.120 |
Why?
|
| Fellowships and Scholarships | 1 | 2014 | 53 | 0.110 |
Why?
|
| Cystocele | 2 | 2017 | 4 | 0.110 |
Why?
|
| Meta-Analysis as Topic | 1 | 2012 | 43 | 0.100 |
Why?
|
| Internet | 1 | 2014 | 203 | 0.100 |
Why?
|
| Biomedical Research | 1 | 2014 | 169 | 0.100 |
Why?
|
| Extracellular Matrix | 2 | 2011 | 245 | 0.100 |
Why?
|
| Cadaver | 2 | 2016 | 163 | 0.100 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 502 | 0.100 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2010 | 45 | 0.090 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2010 | 19 | 0.090 |
Why?
|
| Regeneration | 1 | 2011 | 170 | 0.090 |
Why?
|
| Credentialing | 1 | 2009 | 9 | 0.090 |
Why?
|
| Benzofurans | 1 | 2009 | 5 | 0.090 |
Why?
|
| Pyrrolidines | 1 | 2009 | 15 | 0.090 |
Why?
|
| Stem Cell Transplantation | 1 | 2011 | 210 | 0.080 |
Why?
|
| Costs and Cost Analysis | 1 | 2009 | 100 | 0.080 |
Why?
|
| Cystectomy | 1 | 2010 | 105 | 0.080 |
Why?
|
| Carbachol | 1 | 2008 | 5 | 0.080 |
Why?
|
| BCG Vaccine | 1 | 2008 | 8 | 0.080 |
Why?
|
| Phenylephrine | 1 | 2008 | 28 | 0.080 |
Why?
|
| Tissue Culture Techniques | 1 | 2008 | 41 | 0.080 |
Why?
|
| Probability | 1 | 2008 | 160 | 0.080 |
Why?
|
| Muscle, Smooth | 1 | 2008 | 74 | 0.080 |
Why?
|
| Adjuvants, Immunologic | 1 | 2008 | 54 | 0.080 |
Why?
|
| Hematuria | 1 | 2008 | 11 | 0.080 |
Why?
|
| Reference Values | 1 | 2008 | 255 | 0.080 |
Why?
|
| Patient Selection | 1 | 2010 | 289 | 0.080 |
Why?
|
| Random Allocation | 1 | 2008 | 220 | 0.080 |
Why?
|
| Ovariectomy | 1 | 2008 | 152 | 0.080 |
Why?
|
| Tissue Scaffolds | 1 | 2011 | 412 | 0.080 |
Why?
|
| Robotics | 1 | 2009 | 124 | 0.080 |
Why?
|
| Biological Products | 1 | 2009 | 78 | 0.070 |
Why?
|
| Embolization, Therapeutic | 1 | 2008 | 88 | 0.070 |
Why?
|
| Pyelonephritis, Xanthogranulomatous | 1 | 2007 | 2 | 0.070 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2010 | 194 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 600 | 0.070 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 545 | 0.070 |
Why?
|
| Feasibility Studies | 2 | 2018 | 294 | 0.070 |
Why?
|
| Suture Techniques | 1 | 2007 | 60 | 0.070 |
Why?
|
| Primates | 2 | 2017 | 111 | 0.070 |
Why?
|
| Kidney Neoplasms | 1 | 2008 | 201 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 1092 | 0.070 |
Why?
|
| Prolapse | 1 | 2005 | 5 | 0.070 |
Why?
|
| Fascia | 1 | 2005 | 10 | 0.070 |
Why?
|
| Nephrectomy | 1 | 2007 | 126 | 0.070 |
Why?
|
| Phenotype | 2 | 2020 | 656 | 0.070 |
Why?
|
| Adenocarcinoma | 1 | 2008 | 315 | 0.060 |
Why?
|
| Laparoscopy | 1 | 2007 | 171 | 0.060 |
Why?
|
| Pyridinium Compounds | 1 | 2004 | 4 | 0.060 |
Why?
|
| Collagen Type III | 1 | 2004 | 13 | 0.060 |
Why?
|
| Cross-Linking Reagents | 1 | 2004 | 17 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 316 | 0.060 |
Why?
|
| Collagen Type I | 1 | 2004 | 40 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2016 | 536 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2016 | 406 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 167 | 0.060 |
Why?
|
| Pelvis | 2 | 2018 | 61 | 0.050 |
Why?
|
| Adolescent | 3 | 2019 | 3571 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2004 | 422 | 0.050 |
Why?
|
| Urinary Tract Infections | 1 | 2020 | 50 | 0.040 |
Why?
|
| Young Adult | 2 | 2019 | 2626 | 0.040 |
Why?
|
| Anesthetics | 1 | 2019 | 18 | 0.040 |
Why?
|
| Vacuum Extraction, Obstetrical | 1 | 2018 | 4 | 0.040 |
Why?
|
| Sexual Behavior, Animal | 1 | 2018 | 9 | 0.040 |
Why?
|
| Perineum | 1 | 2018 | 18 | 0.040 |
Why?
|
| Prostatism | 1 | 2018 | 3 | 0.040 |
Why?
|
| Hemostasis, Surgical | 1 | 2018 | 13 | 0.040 |
Why?
|
| Ejaculation | 1 | 2018 | 2 | 0.040 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2018 | 13 | 0.040 |
Why?
|
| Endosonography | 1 | 2018 | 56 | 0.040 |
Why?
|
| Hernia | 1 | 2017 | 11 | 0.040 |
Why?
|
| Compliance | 1 | 2017 | 13 | 0.040 |
Why?
|
| Pressure | 1 | 2017 | 54 | 0.040 |
Why?
|
| Length of Stay | 1 | 2018 | 315 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2016 | 79 | 0.040 |
Why?
|
| Social Behavior | 1 | 2017 | 65 | 0.030 |
Why?
|
| Chemokines | 1 | 2016 | 38 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2017 | 187 | 0.030 |
Why?
|
| Urine | 1 | 2017 | 68 | 0.030 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2016 | 111 | 0.030 |
Why?
|
| Color | 1 | 2015 | 12 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2015 | 48 | 0.030 |
Why?
|
| Prostate-Specific Antigen | 1 | 2015 | 64 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2015 | 75 | 0.030 |
Why?
|
| Body Weight | 1 | 2017 | 311 | 0.030 |
Why?
|
| Sweden | 1 | 2014 | 14 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2014 | 19 | 0.030 |
Why?
|
| Cystoscopy | 1 | 2014 | 30 | 0.030 |
Why?
|
| Biopsy | 1 | 2014 | 273 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 1345 | 0.030 |
Why?
|
| Matrix Metalloproteinases | 1 | 2011 | 10 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2009 | 57 | 0.020 |
Why?
|
| Urination | 1 | 2008 | 16 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2008 | 191 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 849 | 0.020 |
Why?
|
| Arteries | 1 | 2008 | 68 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2007 | 78 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2009 | 331 | 0.020 |
Why?
|
| Subcutaneous Tissue | 1 | 2004 | 6 | 0.010 |
Why?
|
| Abdomen | 1 | 2004 | 45 | 0.010 |
Why?
|
| Urethral Neoplasms | 1 | 2003 | 6 | 0.010 |
Why?
|
| Metaplasia | 1 | 2003 | 19 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2004 | 118 | 0.010 |
Why?
|
| Equipment Failure | 1 | 2003 | 27 | 0.010 |
Why?
|
| Recurrence | 1 | 2003 | 266 | 0.010 |
Why?
|
| Equipment Design | 1 | 2003 | 172 | 0.010 |
Why?
|
| Skin | 1 | 2004 | 217 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2007 | 920 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2004 | 846 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2003 | 154 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2004 | 911 | 0.010 |
Why?
|